GSK Acquires CureVac's mRNA Vaccines for COVID-19, Flu
The $1.56 billion deal strengthens GSK's vaccine portfolio and provides CureVac with a financial lifeline.
- GSK will pay CureVac €400 million upfront and up to €1.05 billion in milestones.
- The acquisition includes vaccines for COVID-19, seasonal flu, and bird flu in various clinical trial stages.
- CureVac will cut 30% of its workforce to focus on mRNA cancer therapies and other early-stage projects.
- The deal extends CureVac's funding into 2028, allowing a focus on high-value R&D opportunities.
- GSK aims to compete with Moderna, Pfizer, and BioNTech in the mRNA vaccine space.
Reuters 
Investopedia 
Forbes 